FDA Approves First Menthol E-Cigarettes for Adult Sale
The FDA has approved the sale of the first menthol e-cigarettes for adults, recognizing their potential health benefits in reducing traditional cigarette smoking effects. Despite concerns, NJOY Holdings’ products have received authorization, but it’s crucial to note that FDA approval doesn’t mean they’re completely safe. With 27 approved products, the FDA is reviewing the vaping industry. While some criticize the decision, the FDA lifted marketing restrictions on Juul e-cigarettes and the Biden administration delayed a menthol tobacco ban. The approval of menthol e-cigarettes highlights the changing landscape of smoking cessation methods and regulations in the U.S.
FDA Approves New Drug Iqirvo for Autoimmune Liver Disease Treatment
The FDA has approved a new drug, Iqirvo (elafibranor), for treating autoimmune liver disease, specifically primary biliary cholangitis (PBC). PBC can lead to liver damage or failure if left untreated, making early detection crucial. Iqirvo offers a targeted therapeutic approach to manage PBC and prevent complications, marking a significant advancement in autoimmune liver disease treatment.
FDA Classifies Cookie Dough Recall Due to Salmonella Concerns
Nearly 30,000 batches of cookie dough have been recalled due to potential salmonella contamination, prompting the FDA to elevate the risk classification to Class II. The affected products include popular brands like Costco Chocolate Chunk and Panera Chocolate Chipper. Consumers are urged to check for specific lot codes and avoid consuming the recalled items to prevent food poisoning.
FDA Recalls 28 Beverages in 2024 Due to Undisclosed Drugs, Bacteria, and Chemicals
The FDA has recalled 28 beverages in 2024 due to undisclosed drugs, bacteria, and harmful chemicals. From arsenic in Martinelli’s Apple Juice to bacteria in Fiji Water, consumers are urged to be cautious. Stay informed on the latest recalls including Schweppes Zero Sugar Gingerale and PepsiCo’s Mug Root Beer.
FDA Lifts Marketing Ban on Juul Vaping Products
The FDA has lifted the marketing ban on Juul’s vaping products, but the fate of these products is still pending a final decision. Juul’s products will continue to be available for purchase while undergoing a scientific review process. This move signifies a pivotal moment in the evaluation process, emphasizing the need for FDA authorization for all e-cigarette products, including Juul’s. Stakeholders await further developments to determine the future status of Juul’s products in the market.
Expert Panel Votes Against MDMA Therapy for PTSD Treatment
An expert panel in the United States has voted against the use of MDMA therapy for treating PTSD, citing concerns about the drug’s efficacy. Despite promising results from trials, panelists raised doubts about the long-term benefits and potential risks associated with the treatment. The FDA is expected to make a final decision by August 11, while Australia has approved the use of MDMA for therapy sessions.
Cionic’s Neural Sleeve Shows Positive Impact on Multiple Sclerosis Patients in Real-World Study
Discover the positive impact of Cionic’s Neural Sleeve technology on patients with multiple sclerosis. A recent study highlighted improvements in walking challenges, showcasing enhanced foot and ankle mobility. CEO Jeremiah Robison emphasizes the importance of tailored technology for neurologic conditions, offering hope for improved quality of life.
FDA recalls nearly 1.9 million bottles of Fiji water in New York due to contamination concerns
The FDA has issued a recall for nearly 1.9 million bottles of Fiji Natural Artesian Water in New York due to concerns over manganese and bacterial contamination. Consumers are urged to stop using the affected water bottles and seek guidance from the appropriate authorities.
FDA issues Class I recall for t:connect iPhone app due to battery drain glitch in insulin pump
The FDA has issued a Class I recall for the t:connect iPhone app due to a software glitch that drained the batteries of the t:slim X2 insulin pump, leading to potential pump shutdowns. Consumers are advised to monitor pump battery levels closely and update to version 2.7.1 or later to prevent unexpected shutdowns and health risks associated with insulin delivery disruptions.
Groundbreaking Gene Therapy for Sickle Cell Disease Shows Promising Results
Researchers at Children’s Hospital of Philadelphia (CHOP) have published final results of a clinical trial for gene therapy targeting sickle cell disease. The study showed 96.7% of patients did not experience VOCs for at least a year, leading to FDA approval of CASGEVY in December 2023. This groundbreaking therapy, developed using CRISPR technology, has shown promising outcomes in preventing pain episodes and improving quality of life for patients.